.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Fuji
Cantor Fitzgerald
Daiichi Sankyo
Chinese Patent Office
Accenture
Cipla
Boehringer Ingelheim
Mallinckrodt
Teva

Generated: September 26, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022065

« Back to Dashboard
NDA 022065 describes IXEMPRA KIT, which is a drug marketed by R-pharm Us Llc and is included in one NDA. It is available from two suppliers. There are six patents protecting this drug and one Paragraph IV challenge. Additional details are available on the IXEMPRA KIT profile page.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ixabepilone profile page.

Summary for NDA: 022065

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:6
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 022065

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IXEMPRA KIT
ixabepilone
INJECTABLE;IV (INFUSION) 022065 NDA E.R. Squibb & Sons, L.L.C. 0015-1910 0015-1910-12 1 KIT in 1 PACKAGE, COMBINATION (0015-1910-12) * 15 mg in 1 VIAL, SINGLE-USE * 8 mL in 1 VIAL, SINGLE-USE
IXEMPRA KIT
ixabepilone
INJECTABLE;IV (INFUSION) 022065 NDA E.R. Squibb & Sons, L.L.C. 0015-1911 0015-1911-13 1 KIT in 1 PACKAGE, COMBINATION (0015-1911-13) * 45 mg in 1 VIAL, SINGLE-USE * 23.5 mL in 1 VIAL, SINGLE-USE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength15MG/VIAL
Approval Date:Oct 16, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jul 23, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Jul 23, 2022Product Flag?Substance Flag?Delist Request?Y
Patent:► SubscribePatent Expiration:Nov 26, 2018Product Flag?Substance Flag?Delist Request?Y


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
Colorcon
Cipla
Daiichi Sankyo
Citi
Fuji
QuintilesIMS
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot